These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 33728583

  • 1. Translating the Investigator's Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis.
    Thyssen JP, Zang C, Neary MP, Bushmakin AG, Cappelleri JC, Cha A, Russo C, Luger TA.
    Dermatol Ther (Heidelb); 2021 Jun; 11(3):845-853. PubMed ID: 33728583
    [Abstract] [Full Text] [Related]

  • 2. Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis.
    Eichenfield LF, Stein Gold LF, Lynde C, Guenther L, Greenberger S, Chu CY, Ghodsi Z, Vlahos B, Sanders P, Cha A, Canosa JM.
    Dermatol Ther (Heidelb); 2024 Apr; 14(4):875-892. PubMed ID: 38546803
    [Abstract] [Full Text] [Related]

  • 3. Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years.
    Luger TA, Hebert AA, Zaenglein AL, Silverberg JI, Tan H, Ports WC, Zielinski MA.
    Paediatr Drugs; 2022 Mar; 24(2):175-183. PubMed ID: 35292919
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities.
    Spergel JM, Blaiss MS, Lio P, Kessel A, Cantrell WC, Takiya L, Werth JL, O'Connell MA, Zang C, Cork MJ.
    Allergy Asthma Proc; 2021 Sep 01; 42(5):425-431. PubMed ID: 34474712
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Relationship Among Treatment, Pruritus, Investigator's Static Global Assessment, and Quality of Life in Patients with Atopic Dermatitis.
    Simpson EL, Tom WL, Bushmakin AG, Cappelleri JC, Yosipovitch G, Ständer S, Luger T, Sanders P, Gerber RA, Myers DE.
    Dermatol Ther (Heidelb); 2021 Apr 01; 11(2):587-598. PubMed ID: 33751495
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
    Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, Eichenfield LF, Forsha DW, Rees WC, Simpson EL, Spellman MC, Stein Gold LF, Zaenglein AL, Hughes MH, Zane LT, Hebert AA.
    J Am Acad Dermatol; 2016 Sep 01; 75(3):494-503.e6. PubMed ID: 27417017
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area.
    Silverberg JI, Tallman AM, Ports WC, Gerber RA, Tan H, Zielinski MA.
    Acta Derm Venereol; 2020 Jun 11; 100(13):adv00170. PubMed ID: 32318744
    [Abstract] [Full Text] [Related]

  • 15. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.
    Ahmed A, Solman L, Williams HC.
    Br J Dermatol; 2018 Mar 11; 178(3):659-662. PubMed ID: 29205284
    [Abstract] [Full Text] [Related]

  • 16. Demographics and Baseline Disease Characteristics of Early Responders to Crisaborole for Atopic Dermatitis.
    Stein Gold LF, Takiya L, Zang C, Sanders P, Feldman SR.
    J Drugs Dermatol; 2020 Jun 01; 19(6):619-624. PubMed ID: 32574023
    [Abstract] [Full Text] [Related]

  • 17. Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families.
    Simpson EL, Paller AS, Boguniewicz M, Eichenfield LF, Feldman SR, Silverberg JI, Chamlin SL, Zane LT.
    Dermatol Ther (Heidelb); 2018 Dec 01; 8(4):605-619. PubMed ID: 30345457
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.